Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Italy

CMS Adonnino Ascoli & Cavasola Scamoni has developed a broad expertise in the field of life sciences. The firm's life sciences practice includes the assistance of clients which operate in the fields of pharmaceuticals, biotechnology medical devices and more generally health care services. We regularly advise life science companies on corporate governance matters and licensing and contracts, as well as day-to-day corporate issues. The Team can count on professionals “borrowed” on a regular basis, to life sciences from other departments of the firm including team of corporate and intellectual property professionals who can boast a significant experience securing and defending patent positions and regulatory law issues in order for companies to comply with the Italian regulatory law.

Read more Read less

Choose area

    Pharmaceuticals

    Today the pharmaceutical industry is rapidly growing. This is a highly complex industry and represents one of the fastest growing on the market.

    Read more

    Feed

    Show only
    CMS Ex­pert Guide to Ad­vert­ising of Medi­cines and Med­ic­al...
    26 May 20
    European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
    The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
    CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
    22 May 20
    For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject...
    In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
    23 Mar 20
    Cov­id-19 in Italy: sim­pli­fied pro­ced­ures for phar­ma­ceut­ic­als...
    04 May 20
    EPO Board of ap­peal re­mits to ex­amin­ing di­vi­sion when pri­or art search...
    In Mod­el de­term­in­a­tion sys­tem/Ac­cen­ture Glob­al Ser­vices Lim­ited (Case T-1159/15), the board of ap­peal finds that need to per­form a pri­or art search con­sti­tutes a spe­cial reas­on to re­mit the ap­peal ap­plic­a­tion...
    09/04/2019
    CMS al fianco della so­ci­età belga Medi-Mar­ket S.A....
    30 Apr 20
    USPTO finds an in­ven­tion cre­ated by an AI ma­chine is not pat­entable
    The US Pat­ent and Trade Mark Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The USPTO ac­cep­ted the in­dic­a­tion...
    06/03/2019
    The European Com­mis­sion sets new rules for the qual­ity...
    17 Apr 20
    Is a pri­vacy-friendly use of mo­bile ap­plic­a­tions to com­bat COV­ID-19...
    A Pan-European Ap­proach to the Use of Mo­bile Apps and Mo­bile Data With its Re­com­mend­a­tion of 8 April 2020 on steps and meas­ures to de­vel­op a com­mon ap­proach to the use of mo­bile ap­plic­a­tions and mo­bile...
    01/02/2019
    Get­ting the Deal Through – Life Sci­ences 2019
    27 Mar 20
    Man­aging clin­ic­al tri­als un­der COV­ID-19: New EU guid­ance is­sued for...
    The COV­ID-19 pan­dem­ic has had a dra­mat­ic im­pact on European health sys­tems, whose pri­or­ity first and fore­most is the treat­ment of pa­tients suf­fer­ing from this dis­ease both in the in-pa­tient and out-pa­tient...